16 millones+ hojas de datos de seguridad libremente buscables con descargas en PDF.

The global Safety Data Sheet (SDS) Management market is experiencing robust growth, driven by increasing regulatory compliance mandates, stringent workplace safety standards, and the rising adoption of digital technologies across various industries. The market, estimated at $2 billion in 2025, is projected to exhibit a Compound Annual Growth Rate (CAGR) of 12% from 2025 to 2033, reaching approximately $6 billion by 2033. This growth is fueled by the escalating need for efficient SDS management solutions that streamline the handling, storage, access, and distribution of Safety Data Sheets across diverse organizational structures and geographical locations. Furthermore, the expanding adoption of cloud-based SDS management systems is significantly accelerating market expansion, providing businesses with enhanced accessibility, improved collaboration, and reduced operational costs. Key players like SafeTec, Global Safety Management (GSM), HazCom Compliance, ERA, SiteHawk, 3E Company, and CloudSDS are contributing to market growth through continuous innovation and the development of user-friendly, comprehensive solutions. The market segmentation includes various industry verticals such as manufacturing, healthcare, chemical, and energy, each presenting unique opportunities for SDS management solutions. The restraining factors influencing market growth include the high initial investment costs associated with implementing new systems and the ongoing requirement for regular updates to maintain compliance with evolving regulations. However, the long-term cost savings achieved through improved efficiency, reduced risk of non-compliance penalties, and enhanced workplace safety are likely to outweigh these initial investments. Geographical variations in regulatory frameworks and technological adoption rates also impact market expansion, with North America and Europe expected to dominate the market due to the early adoption of advanced SDS management technologies and stringent safety regulations. Future growth will depend on the continued development of innovative solutions that integrate seamlessly with existing enterprise resource planning (ERP) systems and leverage Artificial Intelligence (AI) for enhanced data management and risk assessment.

The Chemical and Product Categories database (CPCat) catalogs the use of over 40,000 chemicals and their presence in different consumer products. The chemical use information is compiled from multiple sources while product information is gathered from publicly available Material Safety Data Sheets (MSDS). EPA researchers are evaluating the possibility of expanding the database with additional product and use information.

16 millioner+ sikkerhetsdatablader (SDS) fritt søkbare med PDF-nedlastinger.

This database links over 4,000 consumer brands to health effects from Material Safety Data Sheets (MSDS) provided by the manufacturers and allows scientists and consumers to research products based on chemical ingredients.

The Household Products Database of the National Library of Medicine is based on the Consumer Product Information Database ©2001-2013 by DeLima Associates. All rights reserved.

A database of ingredients in brand-name household products linked to health information from Material Safety Data Sheets (MSDS) provided by manufacturers. The database is designed to help answer the following typical questions: *What are the chemical ingredients and their percentage in specific brands? *Which products contain specific chemical ingredients? *Who manufactures a specific brand? How do I contact this manufacturer? *What are the acute and chronic effects of chemical ingredients in a specific brand? *What other information is available about chemicals in the toxicology-related databases of the National Library of Medicine? NLM and its Contractor (the Database Providers) do not test products nor investigate to determine if this information is complete or accurate.

Patient Support Programmes (PSPs) are used by the pharmaceutical industry to provide education and support to consumers to overcome the challenges they face managing their condition and treatment. Whilst there is an increasing number of PSPs, limited information is available on whether these programmes contribute to safety signals. PSPs do not have a scientific hypothesis, nor are they governed by a protocol. However, by their nature, PSPs inevitably generate adverse event (AE) reports. The main goal of the research was to gather all Novartis-initiated PSPs for sacubitril/valsartan, followed by research in the company safety database to identify all AE reports emanating from these PSPs. Core data sheets (CDS) were reviewed to assess if these PSPs contributed to any new, regulatory-authority approved, validated signals. Overall, AEs entered into the safety database from PSPs confirmed no contribution to CDS updates. Detailed review of real-world data revealed tablet splitting or taking one higher dose tablet a day instead of twice daily. This research, and subsequent analyses, revealed that PSPs did not impact safety label changes for sacubitril/valsartan. It revealed an important finding concerning drug utilisation i.e. splitting of sacubitril/valsartan tablets to reduce cost. This finding suggests that PSPs may contribute important real-world data on patterns of medication usage. There remains a paucity of literature available on this topic, hence further research is required to assess if it would be worth designing PSPs for collecting data on drug utilisation and (lack of) efficacy. Such information from PSPs could be important for all stakeholders.

Abstract

The dataset was compiled by the Geological and Bioregional Assessment Program from multiple sources referenced within the dataset and/or metadata. The processes undertaken to compile this dataset are described in the History field in this metadata statement.

Attribution

Geological and Bioregional Assessment Program

History

Physico-chemical data were compiled from US EPA Estimation Programme Interface (EPI Suite). Estimated properties were based on the Simplified Molecular Input Line-Entry System (SMILES), Biowin models 1-7, PHYSPROP. Ecotoxicology data were compiled from chemical safety data sheets, eChemPortal, USEPA ECOTOX, OECD SIDS, ECHA assessments, USEPA (2015/6) reaxys database, NICNAS/IMAP assessments, ECOSAR 2.0.

Material Safety Data Sheets for chemical products are available to laboratory workers for most chemicals and reagents. However because many laboratory workers, whether in research, public health, teaching, etc., are exposed to not only chemicals but infectious substances as well, there was a large gap in the readily available safety literature for employees. These MSDS are produced for personnel working in the life sciences as quick safety reference material relating to infectious micro-organisms. The MSDS are organized to contain health hazard information such as infectious dose, viability (including decontamination), medical information, laboratory hazard, recommended precautions, handling information and spill procedures. The intent of these documents is to provide a safety resource for laboratory personnel working with these infectious substances. Because these workers are usually working in a scientific setting and are potentially exposed to much higher concentrations of these human pathogens than the general public, the terminology in these MSDS is technical and detailed, containing information that is relevant specifically to the laboratory setting. It is hoped along with good laboratory practices, these MSDS will help provide a safer, healthier environment for everyone working with infectious substances. The MSDS is ran by the Public Health Agency of Canada. The Public Health Agency of Canada (PHAC) is the main Government of Canada agency responsible for public health in Canada. PHACs primary goal is to strengthen Canadas capacity to protect and improve the health of Canadians and to help reduce pressures on the health-care system. To do this, the Agency is working to build an effective public health system that enables Canadians to achieve better health and well-being in their daily lives by promoting good health, helping prevent and control chronic diseases and injury, and protecting Canadians from infectious diseases and other threats to their health. PHAC is also committed to reducing health disparities between the most advantaged and disadvantaged Canadians. Because public health is a shared responsibility, the Public Health Agency of Canada works in close collaboration with all levels of government (provincial, territorial and municipal) to build on each others skills and strengths. The Agency also works closely with non-government organizations, including civil society and business, and other countries and international organizations like the World Health Organization (WHO) to share knowledge, expertise and experiences.

Quantitative data on product chemical composition is a necessary parameter for characterizing near-field exposure. This data set comprises reported and predicted information on >75,000 chemicals contained in >15,000 consumer products. The data’s primary intended use is for exposure, risk, and safety assessments. The data set includes specific products with quantitative or qualitative ingredient information, which has been publicly disclosed through material safety data sheets (MSDS) and ingredient lists. A single product category from a refined and harmonized set of categories has been assigned to each product. The data set also contains information on the functional role of chemicals in products, which can inform predictions of the concentrations in which they occur. These data will be useful to exposure and risk assessors evaluating chemical and product safety.

The data set presented here is in the form of a MySQL relational database, which mimics CPDat data available under the ‘Exposure’ tab of the CompTox Chemistry Dashboard (https://comptox.epa.gov/dashboard) as of August 2017.

This web feature service contains location and facility identification information from EPA's Facility Registry System (FRS) for the subset of facilities that link to the Emergency Response Information System (E-PLAN) provides first responders and other emergency response personnel with on-site hazardous chemical information for facilities across the us. It provides EPA’s tier II reporting data along with other important information including maps of all facilities with a specified hazardous material, chemical hazards response information system (CHRIS) data, material safety data sheets (MSDS), chemical profiles, emergency response guidebook (ERG) pages, national fire protection association (NPA) codes, and facility risk management plans (RMPs). Using vigorous verification and data management procedures, FRS integrates facility data from EPA's national program systems, other federal agencies, and State and tribal master facility records and provides EPA with a centrally managed, single source of comprehensive and authoritative information on facilities. This data set contains the subset of FRS integrated facilities that link to E-PLAN facilities once the E-PLAN data has been integrated into the FRS database. Additional information on FRS is available at the EPA website http://www.epa.gov/enviro/html/fii/index.html.

R&D Database provides Vehicle Crash Test data, Biomechanics Test Data, and Component Test Data to support NHTSA's motor vehicle and traffic safety goals.

Data file marketing programs Novartis _30JUN2020 v1.0 (confidential data on file).

1 - Survey - Hospital Survey on Patient Safety Culture 2 - Tables 3 - Output variables (Profissional experience and Training in patient safety

Road Safety Statistics releases [missing hyperlink]

Data download tool [missing hyperlink] for bespoke breakdowns of our data.

These files provide detailed road safety data about the circumstances of personal injury road accidents in GB from 1979, the types of vehicles involved and the consequential casualties. The statistics relate only to personal injury accidents on public roads that are reported to the police, and subsequently recorded, using the STATS19 accident reporting form.

There has been an increasing demand for more up to date information on reported road accidents to be made available to the public, stakeholders and researchers. As a result, the Department for Transport made a dataset covering accidents for the first and second quarters of 2018 in Great Britain available for the first time on data.gov.uk. The data released was an un-validated subset and has been superseded by the full accident dataset for 2018, released after validation for the full year.

All the data variables are coded rather than containing textual strings. The lookup tables are available in the "Additional resources" section towards the bottom of the table.

Please note that the 2015 data were revised on the 29th September 2016. Accident, Vehicle and Casualty data for 2005 - 2009 are available in the time series files under 2014. Data for 1979 - 2004 are available as a single download under 2004 below.

Also includes: Results of breath-test screening data from recently introduced digital breath testing devices, as provided by Police Authorities in England and Wales Results of blood alcohol levels (milligrams / 100 millilitres of blood) provided by matching coroners’ data (provided by Coroners in England and Wales and by Procurators Fiscal in Scotland) with fatality data from the STATS19 police data of road accidents in Great Britain. For cases when the Blood Alcohol Levels for a fatality are "unknown" are a consequence of an unsuccessful match between the two data sets.

ObjectiveSeveral antifungals are available for the treatment of patients with invasive aspergillosis (IA). This study aims to evaluate the relative efficacy and safety of the first-line monotherapies in primary therapy of IA through network meta-analysis (NMA).MethodsWe systematically searched PubMed, Embase, Web of Science, Cochrane Library, China National Knowledge Infrastructure, VIP database, Wanfang database, and China Biology Medicine for randomized controlled trials (RCTs) up to July 2023 that evaluated the efficacy and safety of monotherapies. We performed NMA with a frequentist random effects model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. Primary outcomes were the all-cause mortality at week 12, and secondary outcomes included overall response rate, and incidence of adverse events (AEs) and severe adverse events (SAEs).ResultsA total of three RCTs involving 1,368 participants (four antifungals) were included. The NMA showed that compared to amphotericin B deoxycholate (D-AmB), the triazoles (posaconazole (POS), isavuconazole (ISA) and voriconazole (VCZ)) can improve the overall response rate in primary therapy of IA, but only VCZ and ISA can reduce the all-cause mortality at week 12 for patients with proven and probable IA (VCZ vs D-AmB: RR = 0.66, 95%CI = 0.47–0.93, moderate certainty; ISA vs D-AmB: RR = 0.52, 95%CI = 0 .31–0.86, low certainty). ISA (SUCRA = 93.50%; mean rank, 1.20) seemed to be the most effective therapy in the above population. As to proven, probable, and possible IA patients, the triazoles were superior to D-AmB in terms of reducing all-cause mortality. Furthermore, the risk of AEs and SAEs was comparable for the three triazoles, but the risk of SAEs was significantly higher for D-AmB than others.ConclusionThe efficacy and safety of triazoles are more favorable than D-AmB in the primary therapy of IA, with ISA being the optimal choice.Systematic Review RegistrationPROSPERO CRD42023407632.

Japan PIA: MI: SDS: Acquisition: Oth: Other Financial Corporations (OFC) data was reported at 4,447.000 JPY bn in Oct 2018. This records a decrease from the previous number of 6,068.500 JPY bn for Sep 2018. Japan PIA: MI: SDS: Acquisition: Oth: Other Financial Corporations (OFC) data is updated monthly, averaging 690.450 JPY bn from Jan 2005 (Median) to Oct 2018, with 166 observations. The data reached an all-time high of 6,841.500 JPY bn in Aug 2018 and a record low of 253.100 JPY bn in May 2011. Japan PIA: MI: SDS: Acquisition: Oth: Other Financial Corporations (OFC) data remains active status in CEIC and is reported by Ministry of Finance. The data is categorized under Global Database’s Japan – Table JP.O003: Portfolio Inv Assets (PIA) by Types of Investors - Based on reports from designated Major Investors (MI).

The Magistrates’ and Children’s Courts data included in this report was extracted from the Courtlink database. The data includes all finalised applications for Family Violence Intervention Orders (FVIO) in which the final hearing took place between 1 July 2011 and 30 June 2016. This includes original applications as well as applications for variation, extension and revocation. The analysis of the courts data looks at the number of applications heard in the Magistrates’ and Children’s Courts, the affected family members (AFM) on the application and the person responding to the order. On each application there is one associated respondent however, there can be multiple affected family members.